CWM
NBIX icon

Cordatus Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Cordatus Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,583
Closed -$366K – 179
2025
Q4 		$366K Buy
2,583
+5
+0.2% +$724 0.08% 132
2025
Q3 		$362K Buy
2,578
+8
+0.3% +$1.08K 0.09% 130
2025
Q2 		$323K Buy
2,570
+9
+0.4% +$1.03K 0.08% 137
2025
Q1 		$283K Buy
2,561
+84
+3% +$10.6K 0.08% 132
2024
Q4 		$338K Buy
2,477
+9
+0.4% +$1.11K 0.09% 123
2024
Q3 		$284K Sell
2,468
-9
-0.4% -$1.23K 0.1% 110
2024
Q2 		$341K Sell
2,477
-15
-0.6% -$2.06K 0.13% 101
2024
Q1 		$344K Sell
2,492
-21
-0.8% -$2.87K 0.25% 48
2023
Q4 		$331K Sell
2,513
-32
-1% -$3.68K 0.27% 43
2023
Q3 		$286K Sell
2,545
-51
-2% -$5.37K 0.26% 47
2023
Q2 		$245K Buy
+2,596
New +$254K 0.09% 133

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cordatus Wealth Management's NBIX Position: Q1 2026 in Review

Cordatus Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,583 shares — an estimated $366K sold.

Cordatus Wealth Management first reported a position in NBIX in Q2 2023 and held it in 11 quarters. The position peaked at $366K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Cordatus Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Cordatus Wealth Management sold 2,583 Neurocrine Biosciences shares in Q1 2026, an estimated $366K.
  • Cordatus Wealth Management first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 11 quarters.
  • Cordatus Wealth Management's Neurocrine Biosciences position peaked at $366K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Cordatus Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.